The compensation package comprises 66,000 non-qualified stock options priced at $12.66 per share, matching the Nasdaq closing price on the day preceding the grant. Additionally, the company awarded 33,000 restricted stock units. Both sets of awards follow a standard vesting schedule, with 25% of the shares becoming exercisable or vested on the first anniversary of the grant date, and the remainder distributed over subsequent monthly or annual installments, contingent upon continued employment.

These awards were issued under the 2026 Employment Inducement Incentive Award Plan, which the board of directors adopted in April. The Human Capital Management Committee, consisting entirely of independent directors, approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4). Atrium Therapeutics, which specializes in RNA-based cardiac therapies, currently holds two clinical-stage candidates, ATR 1072 and ATR 1086, focused on treating rare cardiomyopathies.